comunicacio

Scientists discover the immunomodulatory activity of a drug that would improve the efficacy of immunotherapy against breast cancer

Cancer, Molecular Mechanisms and Experimental Therapy in Oncology Program - Oncobell, Transformation and Metastasis / By

The team of Dr. Eva González-Suarez, from the CNIO and IDIBELL, and the team of Dr. Christos Sotiriou, from the Jules Bordet Institute, demonstrate that a drug already used to treat osteoporosis promotes the infiltration of immune cells in breast tumors.

Scientists discover the immunomodulatory activity of a drug that would improve the efficacy of immunotherapy against breast cancer Read More »

The team led by Dr. M. Carolina Florian at IDIBELL receives a European grant of 2 million euros to study bone marrow rejuvenation

Regenerative Medicine Area, Regenerative Medicine Program, Stem Cell Aging / By

With this project, Dr. M Carolina Florian, from the IDIBELL’s Regenerative Medicine Program, aims to improve the survival and quality of life of elderly patients undergoing chemotherapy.

The team led by Dr. M. Carolina Florian at IDIBELL receives a European grant of 2 million euros to study bone marrow rejuvenation Read More »

IDIBELL has held a meeting with the best Healthtech projects

Innovation / By

The most innovative technology projects in the healthcare sector were presented this November 26th at the third edition of the Accelerator Meeting Point (AMP). The digital meeting allowed different IDIBELL entrepreneurs and invited entities from the HealthTech/Biotech sector to espouse their projects to investors and pharmaceutical companies to obtain financing.

IDIBELL has held a meeting with the best Healthtech projects Read More »

La Marató will finance with 1.5 million euros 10 IDIBELL projects in rare diseases

Breast cancer, Cancer, Cardiovascular, Respiratory and Systemic Diseases and cellular aging Program, Digestive system, diagnostics, pharmacogenetics, care support and clinical prevention Program, Genes, Disease and Therapy Program, Hematopoietic Stem Cell Biology And Leukemogenesis, Hereditary cancer , Human Molecular Genetics, Infectious disease and transplantation Program, Molecular Mechanisms and Experimental Therapy in Oncology Program - Oncobell, Nephrology and renal transplantation, Neurometabolic diseases , Neuroscience Area, Neuroscience Program, Pharmacotherapy, Pharmacogenetics and Pharmaceutical Technology , Regenerative Medicine Area, Regenerative Medicine Program, Stem cells and Neurodegenerative diseases, Synovial inflammation and bone metabolism , Translational Medicine Area / By

IDIBELL has been one of the institutions with more funded projects, up to 10, of which it leads 7, and participates in 3 more projects as a collaborator.

La Marató will finance with 1.5 million euros 10 IDIBELL projects in rare diseases Read More »

New biomedical breakthroughs of Bellvitge, live streaming on November 28th

Cancer, Neuroscience Area, Outreach and education, Regenerative Medicine Area, Translational Medicine Area / By

Next Saturday, November 28th, researchers of Bellvitge will present their most recent investigations to the general public. The new website Sinergia will broadcast a wide program of virtual talks. Sinergia has been specifically released to celebrate the first virtual edition of the Festival for the Research and Innovation in Health of L’Hospitalet.

New biomedical breakthroughs of Bellvitge, live streaming on November 28th Read More »

The combination of two immunomodulatory drugs could be beneficial for more severe Covid-19 patients

Cardiovascular, Respiratory and Systemic Diseases and cellular aging Program, Translational Medicine Area / By

A total of 44 researchers from the Bellvitge Biomedical Research Institute (IDIBELL) and Bellvitge University Hospital (HUB) sign an article in the International Journal of Infectious Diseases, where they demonstrate the beneficial effect of the use of corticosteroids added to tocilizumab treatment to improve the prognosis of critical patients of Covid-19.

The combination of two immunomodulatory drugs could be beneficial for more severe Covid-19 patients Read More »

Some drugs used to reduce stomach acid may increase false positives in the colon and rectal cancer screening

Cancer, Colorectal Cancer, Molecular Mechanisms and Experimental Therapy in Oncology Program - Oncobell / By

A new study analyzes the influence of proton pump inhibitor drugs on the risk of false positives in an immunological fecal occult blood test, a test used to detect colorectal cancer.

Some drugs used to reduce stomach acid may increase false positives in the colon and rectal cancer screening Read More »

Bellvitge will study the application of artificial intelligence in the treatment of Covid-19 in ICUs

Infectious disease and transplantation Program, Innate Immunity and Pathology of the Critical patient, Translational Medicine Area / By

The Intensive Medicine Service of the Bellvitge University Hospital (HUB) participates, through the Bellvitge Biomedical Research Institute (IDIBELL), in the European ENVISION project, which will develop an intelligent decision support system to improve the monitoring and treatment of patients with Covid-19 in ICUs.

Bellvitge will study the application of artificial intelligence in the treatment of Covid-19 in ICUs Read More »

IDIBELL celebrates the Kickoff Meeting of the projects financed by 2019 La Marató de TV3 Foundation call

Sin categorizar / By

Today, the Teams platform hosted the IDIBELL Kickoff Meeting La Marató 2019, aimed at all those researchers who have obtained a research project within the “Convocatòria 2019 per a l’adjudicació d’ajudes econòmiques a projectes de recerca de càncer” by La La Marató de TV3 Foundation.

IDIBELL celebrates the Kickoff Meeting of the projects financed by 2019 La Marató de TV3 Foundation call Read More »

Scroll to Top